XML 50 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2023
Summary of Significant Accounting Policies [Abstract]  
Schedule of Changes in the Allowance for Credit Losses The changes in the allowance for credit losses in each of the years ended December 31, 2023 and 2022, were as follows:
   2023   2022 
Balance at beginning of year  $352,043   $241,219 
Bad debt expense   665,973    363,512 
Write-offs   (778,844)   (252,688)
Balance at end of year  $239,172   $352,043 
Schedule of Revenue is Earned from Life Sciences Companies A break down is set forth in the table below
   2023   2022 
Revenue recognized over time  $63,527,477   $55,437,418 
Revenue recognized at a point in time   7,994,029    7,012,738 
Total Revenue  $71,521,506   $62,450,156 

 
Schedule of Pay Any Dividends in the Future
   2023   2022 
Expected dividend yield   0%   0%
Risk free interest rate   3.76% - 4.74%    0.82% - 4.38%
Expected option term   3.5 years    3.5 years 
Turnover/forfeiture rate   0%   0%
Expected volatility   67% - 72 %   68% - 71 %
Weighted average grant date fair value  $6.58   $12.82 
Schedule of Weighted Average Shares Outstanding and the Basic and Diluted Earnings Per Common Share The computation of weighted average shares outstanding and the basic and diluted earnings per common share for the years ended December 31, 2023 and 2022 consisted of the following:
   Year ended December 31, 2023 
   Net (Loss)   Shares   Per Share
Amount		 
Basic EPS  $(17,565,866)   17,124,801   $(1.03)
Effect of dilutive securities   —    —    — 
Diluted EPS  $(17,565,866)   17,124,801   $(1.03)
   Year ended December 31, 2022 
   Net Income   Shares   Per Share
Amount		 
Basic EPS  $(11,438,440)   17,783,992   $(0.64)
Effect of dilutive securities   —    —    — 
Diluted EPS  $(11,438,440)   17,783,992   $(0.64)